Vertex to Acquire Crinetics for $10B, Shares Double in After-Hours
CRNX•Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a deal valued at $10 billion, offering shareholders a substantial premium on Monday’s closing price. Crinetics shares doubled in after-hours trading as investors reacted to the acquisition and potential expansion of Vertex’s rare endocrine therapy portfolio.
1. Vertex Announces $10B Acquisition
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a transaction valued at $10 billion, underscoring the strategic importance of Crinetics’ portfolio. The deal offers Crinetics shareholders a significant premium over the company’s last closing price and marks one of the largest biotech acquisitions of the year.
2. Shares Soar in After-Hours Trading
Following the announcement, Crinetics stock doubled in after-hours trading, reflecting strong investor enthusiasm for the deal. The spike pushed the share price to more than twice its Monday closing level before regular market hours resumed.
3. Expansion of Rare Endocrine Pipeline
The acquisition brings Crinetics’ pipeline of endocrine and metabolic disorder therapies, including late-stage candidates, into Vertex’s research and development portfolio. This move is expected to boost Vertex’s position in rare disease treatments and diversify its long-term growth drivers.
